USC and CHLA have purchased the clinical trials management system, OnCore, which is being deployed across USC and CHLA. OnCore will bring together data from multiple sources to help streamline the initiation, management, and financial accounting of clinical research studies. Keck Medicine CIO Joshua Lee is leading the implementation of OnCore, including the integration of multiple existing data sources and numerous business units with disparate and sometimes redundant processes. This team is assisted by the CIO of CHLA, TJ Malseed and by the Director of Sponsored Projects, Samantha Westcott, among others. As part of the project, current processes and workflows related to the life cycle of a clinical trial have been thoroughly examined and evaluated in order to optimize study management processes. In addition, our core team from USC and CHLA participated in immersion training in December. The next phase of training will expand to super users, followed by end-user training in the spring. Pilot studies are scheduled to commence in June and anticipate all new studies to begin enrolling with the new system starting in July 2015. With the addition of OnCore, there are also plans underway to integrate with the EHR systems in order for clinicians and investigators to be able to identify clinical trial opportunities for patients during their clinic visits. When OnCore is fully operational, it will provide a single point of access for managing the business and operational aspects of clinical trials across USC and CHLA.

From the moment of study inception, as feasibility and scientific merit are considered, through the budgeting and calendaring process, the system allows for both facilitated creation of protocols and the centralized tracking of progress of a study towards accrual. With easy-to-use tools to enroll participants and track their completion of the indicated protocol services, the study coordinators and principal investigators will have a more enhanced and at the same time more comprehensive clinical research experience. The ability to centrally monitor the enrollment of various trials will also result in more efficient use of research resources.